12 Biotech Accelerators That Actually Move the Needle for Founders

Accelerators and incubators are just two routes early-stage biotech startups can take toward company formation, growth, and commercialization. Both programs offer mentorship, resources, and investor access, but their structures and timelines differ. 

For founders, however, the biggest benefits often extend beyond funding or lab space. To better understand their impact, we spoke with Sophia Yen, MD, MPH, CEO & Co-Founder of Pandia Health, who participated in both the StartX and Springboard accelerator programs. Looking back, Yen said joining the programs was “absolutely worth it,” pointing to the value of the communities she gained access to. She described the experience as “an instant large community of supporters and advisors and people who had done this before from whom I could learn and get help.”

There are three main categories to consider when deciding which program or programs to apply to:  

• Lab-space incubators give participating startups access to lab space and offices to support research and product development.

• Cohort accelerators typically have defined start and end dates and include a structured curriculum, mentorship, and investor engagement, often through a hybrid or full-time in-person setup. 

• Venture-creation nonprofits help scientists and researchers transition into entrepreneurship while providing startup support and, in some cases, initial funding.

There's also the matter of equity. Incubator programs rarely take equity as part of their participation model, whereas accelerator participants often give up a percentage of ownership in their startup in exchange for mentorship, resources, and funding. Venture-creation nonprofits may take equity or provide grants or other forms of non-dilutive funding instead.

Deciding whether or not to apply to an accelerator or incubator comes down to a few key considerations: your startup's stage, funding needs, and long-term goals. From there, consider the types of access or resources you'll benefit most from, whether it is on-site wet labs to test your technology further or direct access to mentors with deep experience in your field. 

Yen also highlighted the importance of investor access, pointing to StartX's pitch day, which gave founders access to “more than 300 VCs in one day.” She noted that this type of opportunity would be difficult to recreate independently. At the same time, she cautioned founders that “it’s hard to know which incubators are worth your time and which ones are not,” making it important to carefully evaluate each program before applying.

From lab-space incubators like LabCentral to cohort accelerators like JLABS, here are 12 biotech accelerators and incubators every founder should know. 

Type: Lab-space incubator (nonprofit)

Best for: Early wet-lab therapeutics, diagnostics, and platform biotech founders who need to be physically embedded in a top cluster.  LabCentral is also expanding to support companies using AI and advanced computing via its new AI BioHub track. 

What you get: Fully permitted BSL-2 wet lab and office space, shared core equipment, with waste handling and compliance already set up, plus community programming and sponsor-funded residency competitions (e.g., Biogen and Novo Nordisk "Golden Ticket" prizes)

Cost of entry: No equity taken. Paid, month-to-month bench/lab rental (pricing reduced for 2026). The new "LabCentral First" track offers eligible first-time founders the opportunity to compete for admission, or six months free.

Wet-lab access: Yes

How to get in: Apply for residency directly. Applications are evaluated based on the strength of the science, team, and stage. Rolling admission based on space availability, with no fixed cohort dates.

Track record: According to its latest impact report, 30 new companies were supported in 2025, 737 jobs were created, and 22 new clinical trials were launched.

Location: Cambridge, MA (Kendall Square and the Harvard Enterprise Research Campus). On-site residency is highly encouraged. 

The take: The default choice if you need high-quality wet-lab infrastructure without giving up equity in your company.

Type: Lab-space incubator (membership network)

Best for: Wet-lab startups of any therapeutic or platform focus that want flexibility across multiple U.S. biotech hubs rather than being tied to one city. 

What you get: Turnkey shared lab and office space (tissue culture suites, qPCR, HPLC, flow cytometry, microscopy, plate readers, and fume hoods). Compliance and permitting are handled by the staff, along with access to sponsors and the mentor network. BioLabs also emphasizes operational support so founders don't spend time managing facilities.

Cost of entry: No equity taken. Companies pay a monthly membership fee for laboratory space, with pricing varying by location and laboratory configuration. Flexible month-to-month terms are common across the network.

Wet-lab access: Yes, at every location

How to get in: Apply directly through the site. Applicants are evaluated based on factors such as space availability at their chosen location, industry, and team fit, rather than through a competitive cohort process.

Track record: Member companies have collectively raised more than $5 billion.

Location: More than 15 locations across major U.S. and international biotech hubs, including Boston/Cambridge, New Haven, New York, Princeton, Philadelphia, Raleigh-Durham, Dallas, San Diego, Los Angeles, Chicago, Rochester (Minnesota), Burlington (Vermont), Paris, Heidelberg, Berlin, Munich, and Tokyo. On-site residency is required, and applicants select their desired location when applying. 

The take: One of the strongest options for founders who want BioLabs-quality infrastructure but need a location outside Boston or the Bay Area. BioLabs also has a real presence in southern cities like Dallas and Raleigh-Durham, as well as university-affiliated sites that most networks skip.

Type: Lab-space incubator with attached venture capital (hybrid)

Best for: Therapeutics and medtech founders in emerging or second-tier biotech markets who need both space and venture support. 

What you get: Fully equipped wet/dry lab space plus Portal's "Crafted Capital" model, which combines seed investment, hands-on operational support, and direct introductions to its investor network.

Cost of entry: Dilutive. Lab memberships are available on a fee basis. If Portal invests through one of its venture funds, the relationship becomes dilutive, with equity terms negotiated on a case-by-case basis.

Wet-lab access: Yes

How to get in: Apply to the specific regional site. Applicants are evaluated based on their science, team, and fit with the local ecosystem and university partnerships (such as the University of Utah and BYU for the Salt Lake City site). 

Track record: Its portfolio spans therapeutics, medtech, and diagnostics. Portal provides funding from the earliest seed stages through Series A. 

Location: Chicago HQ with lab sites in Chicago (Fulton Labs and the UChicago Science Incubator), Houston, New Brunswick, New Jersey, Providence, Rhode Island, and Woodbine Labs in Salt Lake City (opening in 2027). Portal also has an expanding international presence. Most companies are expected to work on-site to take advantage of shared facilities and programming.

The take: An excellent fit for founders in emerging biotech ecosystems who want lab space, early capital, and operational support from a single organization. Portal is especially strong in markets such as Utah, the Midwest, Texas, and the Northeast, where it works closely with research institutions to help commercialize scientific discoveries.

Type: Lab-space incubator, operated by a nonprofit venture-creation organization (subsidiary of BioSTL)

Best for: Therapeutics, medtech, and agtech founders — St. Louis's ecosystem skews more agriculture/plant-science than the coasts, a genuine point of difference

What you get: Co-working wet lab space (first model of its kind in the country) inside the Cortex Innovation District, plus access to BioGenerator Ventures' investment arm and the broader BioSTL ecosystem 

Cost of entry: Lab-space membership is paid and non-dilutive; separately, BioGenerator Ventures does take equity when it invests directly, so cost depends on whether you're just renting bench space or also raising from BioGenerator itself. 

Wet-lab access: Yes

How to get in: Applicants apply directly and are evaluated on their science, commercialization potential, and fit—BioGenerator's focus areas are therapeutics, medtech, and agtech. Currently, there is no fixed cohort calendar. 

Track record: Ecosystem companies include Geneoscopy, CoverCress, and MediBeacon; 50+ companies and 225 users currently in the lab space. Two 2026 portfolio companies (Buck Surgical, Spearhead Bio) were named local "Startups to Watch."

Location: St. Louis, MO. On-site residency required

The take: One of the country's strongest nonprofit biotech incubators for founders interested in therapeutics or medtech. It offers high-quality lab space and commercialization support in a lower-cost ecosystem than major coastal hubs, with strong connections to investors and research institutions.

Type: University-affiliated wet-lab incubator

Best for: Early-stage life science startups that need flexible wet-lab space, shared scientific equipment, and close access to UC Berkeley's research ecosystem. While many tenants have UC Berkeley ties, companies can apply from anywhere and don’t require prior affiliation with the university. 

What you get: Flexible wet-lab and office space, from individual benches to private labs, as well as shared BSL-2 facilities and scientific equipment. The incubator also facilitates access to UC Berkeley research facilities and offers a series of networking and educational programs. The incubator is operated in partnership with QB3, giving companies access to entrepreneurship programming, mentors, investor events, and the broader Bay Area life science ecosystem.

Cost of entry: Paid, non-dilutive membership. Lab benches, office space, and memberships are available through flexible monthly leases. Bakar Bio Labs does not take equity in tenant companies. 

Wet-lab access: Yes, Bakar Labs offers fully equipped BSL-2 laboratories with shared instrumentation, tissue culture facilities, analytical equipment, and optional private lab space. 

How to get in: Startups can apply directly, and applications are reviewed on a rolling basis. Acceptance criteria include the company's scientific and commercial fit, facility needs, and stage of development. There is no cohort model.

Track record: Since opening in 2022, Bakar Bio Labs has reached full occupancy, supporting roughly 40–50 tenant and alumni companies that have collectively raised more than $600 million in funding. Notable tenants include Profluent, Renasant Bio, ResVita Bio, and Vivere Oncotherapies.

Location: Berkeley, California (UC Berkeley campus). On-site residency is required for lab tenants.

The take: One of the premier university-affiliated biotech incubators in the U.S. If your startup needs world-class wet-lab infrastructure, opportunities to collaborate with UC Berkeley researchers, access selected campus resources, and connections to investors without giving up equity, Bakar Bio Labs is among the strongest options available.

Type: No-equity residency / cohort-adjacent life science innovator that sits between a lab-space incubator and a traditional accelerator. It has no fixed curriculum but does have a defined, competitive application process.

Best for: Therapeutics, medtech, diagnostics, consumer health, and digital health founders who want big-pharma-caliber validation and network access without giving up ownership. 

What you get: Lab and office space, specialized equipment, entrepreneurial programming, mentorship, and access to J&J's partner and investor network, with a "no strings attached" model.

Cost of entry: No equity taken, no IP claims, and no confidential information required to apply. Paid lab or virtual membership. 

Wet-lab access: Yes, at physical sites. 

How to get in: Rolling application via non-confidential documentation, including science/technology background, IP coverage, competitive landscape, team bios, and a 12–18 month project plan. Applications are evaluated based on transformational science, significant unmet need, team strength, and alignment with J&J's strategic interest areas. Founders typically receive a 'yes' or 'no' within several weeks of applying. 

Track record: JLABS reports 200+ member companies (current and alumni), $65B+ in financial and strategic relationships secured by residents, and 18 company acquisitions.

Location: JLABS has sites across North America, EMEA, and Asia-Pacific. JLABS is located at LabCentral in Cambridge, MA, as well as in San Diego, San Francisco, and Shanghai, plus several virtual sites. Virtual membership is designed for startups that do not require lab or office space.  

The take: One of the strongest no-equity options if you want real wet-lab access and pharma-scale connections. The tradeoff is a highly competitive, non-confidential application process with strong alignment expected with J&J's therapeutic areas.

Type: Cohort accelerator with capital

Best for: Very early-stage (often pre-seed) therapeutics, synthetic biology, engineered biology, and increasingly AI-enabled biology founders who need both funding and wet-lab access fast.

What you get: Seed capital, in-house BSL-2 wet labs, an intensive approximately 4-month structured program with scientific and business mentorship, a Demo Day for investors, and extensive founder office hours and access to SOSV's global network of investors and technical experts.

Cost of entry: Dilutive. Dilutive. Companies typically receive a $250,000 initial investment in exchange for approximately 6–8% equity. Eligible startups may also access additional follow-on funding through SOSV and the Genesis Consortium such as up to another $250K via SAFE through the Genesis Consortium at a $6M cap, for up to $525K total.

Wet-lab access: Yes, on-site at both locations.

How to get in: Rolling application; written application, screening calls covering the team, technology, market, and technical plan, followed by interviews before an offer.

Track record: Funded 300+ companies historically under the IndieBio name. Alumni have raised over $3.2B in follow-on capital, and the portfolio includes NotCo and UPSIDE Foods.

Location: San Francisco and New York. Full-time, in-person residency required. 

The take: Although SOSV increasingly markets its life science accelerators under the broader SOSV umbrella, the IndieBio program, team, and investment philosophy remain the foundation of its San Francisco and New York offerings. For founders seeking hands-on scientific mentorship, lab access, and early capital, it remains one of the world's premier biotech accelerators.

Type: Cohort accelerator with capital (general accelerator, not biotech-specific)

Best for: Platform, tools, and digital-bio founders, including software-heavy biology, lab automation, AI for biology, and clinical trial software, rather than capital-intensive wet-lab therapeutics.

What you get: $500,000 in funding, a 3-month in-person batch in San Francisco with weekly partner office hours, a Demo Day attended by 1,000+ investors, and lifetime alumni network access. 

Cost of entry: Dilutive. $125,000 for 7% equity (fixed, post-money SAFE) plus $375,000 on an uncapped SAFE with a Most Favored Nation clause, for a total of $500K. The terms are non-negotiable and identical for every company.

Wet-lab access: No in-house lab space. YC instead helps founders connect with third-party lab providers and negotiate preferred access or pricing. 

How to get in: Written application plus a short interview for promising applicants. The acceptance rate is roughly 1% to 2% from approximately 25,000 applications per batch. There’s no biotech-specific track, but YC publishes a Request for Startups highlighting the categories it's actively seeking. 

Track record: 120+ biotech-tagged companies funded to date, including Benchling and Ginkgo Bioworks. To date, 17 YC companies have gone public across all sectors.

Location: San Francisco (in-person batch required). YC invests in companies incorporated in the United States, Canada, Singapore, and the Cayman Islands. Companies outside these areas must create a parent company that is in one of those jurisdictions to participate. 

The take: Excellent for founders building AI-enabled biology, research tools, diagnostics, or scalable biotech platforms who want a world-class founder network and rapid fundraising exposure. Traditional therapeutics and other wet-lab startups can also thrive in YC, but they'll need to secure external lab space and typically plan for larger follow-on financing.

Type: Cohort accelerator, non-dilutive (competition-based, not investment-based)

Best for: Digital health and life-sciences founders (broader than pure wet-lab therapeutics) who want structured mentorship and corporate access without a term sheet. 

What you get: A structured, approximately four-month program with mentorship, investor exposure, customer discovery support, and introductions to healthcare systems, pharmaceutical companies, and strategic partners. Top-performing startups compete for non-dilutive cash awards rather than receiving automatic investment.

Cost of entry: Completely non-dilutive. There is no fee to apply and no equity taken.

Wet-lab access: No. This is a curriculum and mentorship-based program, so wet-lab founders need to secure infrastructure elsewhere.

How to get in: Two rounds of written-application judging by industry-expert panels. The 2026 cohort requires in-person attendance at a Dallas kickoff and a Boston mid-program roadshow.

Track record: The broader MassChallenge alumni network has raised billions. As of March, 2026, $27.1 billion has been invested across 4,486 companies, created tens of thousands of jobs, and includes companies such as Ginkgo Bioworks.

Location: Hybrid program with required in-person events, including a kickoff in Dallas and a mid-program roadshow in Boston.

The take: Strong option for digital health and health-tech founders because it costs nothing to participate. The tradeoff is that funding is competitive and not guaranteed to every admitted company, unlike SOSV's or YC's fixed-check model.

Type: Venture-creation nonprofit (team-formation program, not an investor)

Best for: Academic trainees, including PhDs, postdocs, MDs, and MBAs, who have a scientific idea but no company, co-founder, or business plan yet. The program supports both human health (Bio Track) and sustainability (Eco Track) ventures.

What you get: A structured "mutual-matching" process pairing scientific founders with business co-founders, followed by workshops, weekly mentor office hours, and a final pitch showcase. Participants also receive access to 2,000+ industry mentors and investor introductions.

Cost of entry: Completely free. Nucleate never takes equity or charges fees, and does not require incorporation.

Wet-lab access: No. This is a company formation and curriculum program only.

How to get in: Applications open annually for each Activator cohort, with deadlines varying by chapter (often in October for many North American Bio Track cohorts). Applicants can apply either as inventors with an idea or as contributors seeking to join a team. Local chapter leadership reviews applications, interviews semifinalists, and oversees the team-matching process.

Track record: Nucleate has supported more than 1,300 technologies globally, resulting in 600 companies and over $1 billion in capital. Notable portfolio companies include Manifold Bio, Glyphic Biotechnologies, Junevity, and Vitra Labs. 

Location: There are more than 40 regional chapters globally, plus a Global Virtual Activator track. No physical residency is required. The program is designed to be completed part-time alongside academic or clinical work.

The take: A strong first stop if you're a scientist with an idea but not yet a company. The program is specifically designed to help founders build teams and find co-founders before they're ready for an accelerator.

Type: Venture-creation nonprofit (individual fellowship, not a team program or investor)

Best for: Individual scientist- or engineer-founders in the physical or biological sciences with a specific technology that needs sustained de-risking before it's ready to become a company. 

What you get: At least $350,000 in direct support over two years, including a living stipend, research funding, mentorship, entrepreneurial training, and access to laboratory and research facilities through host institutions.

Cost of entry: Completely non-dilutive. Activate takes no equity and claims no IP rights.

Wet-lab access: No, Activate does not directly provide laboratory space. But they do offer lab access through partner institutions. 

How to get in: Annual competitive application, with the 2026 cohort deadline closing in late October 2025. Applicants must be based in the physical or biological sciences or related engineering, must not yet be ready for full-scale product sales, and must have raised no more than $2M in non-governmental funding at the time of application.

Track record: Since 2015, Activate has supported nearly 300 fellows across the United States who have launched over 230 hard-tech companies. Backed by the National Science Foundation (NSF) and other partners, the fellowship guarantees at least $350,000 in direct support per fellow over two years. 

Location: Five communities: Berkeley, Boston, Houston, New York, and the virtual "Activate Anywhere" track. Residency requirements vary by community.

The take: The most patient source of support on this list, offering two years of runway rather than a three-to-six-month sprint. It's best suited to deep science that genuinely isn't investable yet, rather than founders who already have traction and just need a check.

Type: biotechnology venture studio that helps create and build early-stage biotech companies rather than operating as a traditional cohort accelerator.

Best for: Scientists, researchers, and technical founders with promising biotechnology ideas who need help turning early scientific discoveries into venture-backed companies. Petri focuses on formation-stage biotech companies, particularly in areas such as synthetic biology, therapeutics, and engineered biology.

What you get: Capital, company-building support, access to experienced operators, strategic guidance, and support with forming and scaling biotechnology companies. Unlike a traditional accelerator, Petri works with founders over a longer period to help build companies from the earliest stages rather than running a fixed-duration program. 

Cost of entry: Dilutive. Petri invests in the companies it helps create and takes equity ownership in exchange for capital and company-building support. Specific terms vary by company and stage.

Wet-lab access: No dedicated wet-lab facilities. Petri provides venture-building support and investment rather than operating as a physical laboratory incubator. Companies typically use external lab infrastructure, academic facilities, or third-party incubators for research activities.

How to get in: Petri does not operate a traditional accelerator application process or fixed cohort calendar. It partners with founders and scientific teams developing high-potential biotechnology companies.

Track record: Petri has launched and invested in multiple biotechnology companies, including Matterworks and New Equilibrium Bio, supporting companies from early formation through venture financing.

Location: Boston, Massachusetts.

The take: Petri is best suited for scientists with promising technology but who need help building the company around it. It sits between a traditional accelerator and a biotech venture fund, combining capital with hands-on support for company creation rather than offering only mentorship or a short-term program.